RELIEVE-AD is a single-arm, prospective, observational study in patients with moderate-to-severe atopic dermatitis enrolled in DUPIXENT MyWay® prior to initiating treatment with DUPIXENT. Patients completed multiple surveys over 60 months. At Month 60, participants that responded to the survey at Month 33 and/or Month 48 were recontacted for Month 60 follow-up.2,17
Limitations of analysis:
This patient population was self-selected; those who maintain long-term efficacy and safety may be more likely to participate in such surveys. Similarly, patients were recruited through a DUPIXENT patient support program, which may influence patient perceptions of treatment benefit.2,17